HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Qayumi, A. K. Articles by Poostizadeh, A. Search for Related Content PubMed PubMed Citation Articles by Qayumi, A. K. Articles by Poostizadeh, A.

The Annals of Thoracic Surgery, Vol 52, 1026-1032, Copyright © 1991 by The Society of Thoracic Surgeons

ARTICLES

Effects of platelet-activating factor antagonist CV-3988 in preservation of heart and lung for transplantation

AK Qayumi, WR Jamieson and A Poostizadeh
Department of Surgery, University of British Columbia, Vancouver, Canada.

The preservation of heart and lung for transplantation remains a major concern in extended ischemic intervals. This experiment evaluated the effect of high molecular weight deferoxamine and a platelet-activating factor antagonist (CV-3988) in ischemic reperfused tissue. Heart-lung transplantation was performed in a swine model after 4 hours 45 minutes of ischemia. Animals were divided into three groups. Group A was a control without pharmacological intervention. In group B, high molecular weight deferoxamine, 50 mg/kg, was used, and in group C, platelet-activating factor antagonist CV-3988, 10 mg/kg, was used. The results of functional variables (cardiac index, stroke index, lung water, oxygen and carbon dioxide tensions, alveolar-arterial gradient, and alveolar-arterial ratio) demonstrated superior heart and lung function for groups B and C compared with the control group. These alterations of heart and lung function were significantly less (p less than 0.001) in group C, in which the platelet-activating factor antagonist (CV-3988) was used. The study revealed that formation of hydroxyl radicals and platelet-activating factor play an important role in the pathogenesis of ischemia reperfusion injury. Prevention of hydroxyl radical formation with high molecular weight deferoxamine and inactivation of platelet-activating factor with CV-3988 reduce the ischemia-reperfusion injury significantly.

This article has been cited by other articles:

				O. Cakir, A. Oruc, S. Eren, H. Buyukbayram, L. Erdinc, and N. Eren Does sodium nitroprusside reduce lung injury under cardiopulmonary bypass? Eur. J. Cardiothorac. Surg., June 1, 2003; 23(6): 1040 - 1045. [Abstract] [Full Text] [PDF]

				J. D. Kim, C. J. Baker, R. F. Roberts, S. H. Darbinian, K. A. Marcus, S. M. Quardt, V. A. Starnes, and M. L. Barr Platelet activating factor acetylhydrolase decreases lung reperfusion injury Ann. Thorac. Surg., August 1, 2000; 70(2): 423 - 428. [Abstract] [Full Text] [PDF]

				T. Suda, B. N. Mora, F. D’Ovidio, J. A. Cooper, M. Hiratsuka, W. Zhang, T. Mohanakumar, and G. A. Patterson IN VIVO ADENOVIRUS-MEDIATED ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE TRANSFER AMELIORATES LUNG ALLOGRAFT ISCHEMIA-REPERFUSION INJURY J. Thorac. Cardiovasc. Surg., February 1, 2000; 119(2): 297 - 304. [Abstract] [Full Text] [PDF]

				J. Zhang, W.R. E. Jamieson, H. Sadeghi, K. Gillespie, J. R. Marier, H. Mickleson, and R. McGibbon Strategies of myocardial protection for operation in chronic model of cyanotic heart disease Ann. Thorac. Surg., November 1, 1998; 66(5): 1507 - 1513. [Abstract] [Full Text] [PDF]

				A. K. Qayumi, M. Nikbakht-Sangari, D. V. Godin, J. C. English, K. J. Horley, P. A. Keown, S. P. Lim, D. M. Ansley, and M. S. Koehle The relationship of ischemia-reperfusion injury of transplanted lung and the up-regulation of major histocompatibility complex II on host peripheral J. Thorac. Cardiovasc. Surg., May 1, 1998; 115(5): 978 - 982. [Abstract] [Full Text] [PDF]

				S. Fujino, I. Nagahiro, A. N. Triantafillou, C. H. R. Boasquevisque, M. Yano, J. D. Cooper, and G. A. Patterson Inhaled Nitric Oxide at the Time of Harvest Improves Early Lung Allograft Function Ann. Thorac. Surg., May 1, 1997; 63(5): 1383 - 1389. [Abstract] [Full Text]

				M. Yamashita, R. A. Schmid, S. Fujino, J. D. Cooper, and G. A. Patterson NICORANDIL, A POTENT ADENOSINE TRIPHOSPHATE-SENSITIVE POTASSIUM-CHANNEL OPENER, AMELIORATES LUNG ALLOGRAFT REPERFUSION INJURY J. Thorac. Cardiovasc. Surg., November 1, 1996; 112(5): 1307 - 1314. [Abstract] [Full Text]

				C. J. Serrick, A. Jamjoum, A. Reis, A. Giaid, and H. Shennib AMELIORATION OF PULMONARY ALLOGRAFT INJURY BY ADMINISTERING A SECOND RINSE SOLUTION J. Thorac. Cardiovasc. Surg., October 1, 1996; 112(4): 1010 - 1016. [Abstract] [Full Text]

				M. Yamashita, R. A. Schmid, K. Ando, J. D. Cooper, and G. A. Patterson Nitroprusside Ameliorates Lung Allograft Reperfusion Injury Ann. Thorac. Surg., September 1, 1996; 62(3): 791 - 796. [Abstract] [Full Text]

				K. Okabayashi, A. N. Triantafillou, M. Yamashita, M. Aoe, S. R. DeMeester, J. D. Cooper, and G. A. Patterson CARDIAC AND PULMONARY REPLACEMENTINHALED NITRIC OXIDE IMPROVES LUNG ALLOGRAFT FUNCTION AFTER PROLONGED STORAGE J. Thorac. Cardiovasc. Surg., August 1, 1996; 112(2): 293 - 299. [Abstract] [Full Text]

				R. J. Novick, K. E. Gehman, I. S. Ali, and J. Lee Lung Preservation: The Importance of Endothelial and Alveolar Type II Cell Integrity Ann. Thorac. Surg., July 1, 1996; 62(1): 302 - 314. [Abstract] [Full Text]

				M. Yamashita, R. A. Schmid, K. Okabayashi, K. Ando, J. Kobayashi, J. D. Cooper, and G. A. Patterson Pentoxifylline in Flush Solution Improves Early Lung Allograft Function Ann. Thorac. Surg., April 1, 1996; 61(4): 1055 - 1061. [Abstract] [Full Text]